EZH2型
生物
前列腺癌
表观遗传学
组蛋白
癌症研究
表观遗传疗法
增强子
PRC2
生物信息学
遗传学
癌症
DNA甲基化
转录因子
基因
基因表达
作者
Jonathan B. Coulter,Hariharan Easwaran
出处
期刊:PLOS Biology
[Public Library of Science]
日期:2023-04-27
卷期号:21 (4): e3002081-e3002081
被引量:6
标识
DOI:10.1371/journal.pbio.3002081
摘要
Development of resistance in castration-resistant prostate cancer (CRPC) involves epigenetic pathways. A new study in PLOS Biology demonstrates that combined therapy targeting enhancer of zeste homolog 2 (EZH2) and histone deacetylases (HDACs) may sensitize CRPC to both epigenetic and standard therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI